Therapeutic prospects for mitochondrial disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Until even only a few years ago, the idea that effective therapies for human mitochondrial disorders resulting from dysfunction of the respiratory chain/oxidative phosphorylation system (OxPhos) could be developed was unimaginable. The obstacles to treating diseases caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA), and which had the potential to affect nearly every organ system, seemed overwhelming. However, while clinically applicable therapies still remain largely in the future, the landscape has changed dramatically; we can now envision the possibility of treating some of these disorders. Among these are techniques to upregulate mitochondrial biogenesis, to enhance organellar fusion and fission, to “shift heteroplasmy,” and to eliminate the burden of mutant mtDNAs via cytoplasmic transfer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., & Moraes, C. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911570106 · Cited by 600 · cited 2×
“PGC-1α stimulates the biogenesis of all mitochondria, whether dysfunctional or not [28], whereas the RRFs in patients, even those who are heteroplasmic, are composed almost exclusively of mitochondria harboring mutated mtDNAs, with essentially no proliferation of mitochondria harboring normal mtDNAs [30,31].”
BackgroundRetractedParkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 2×
“This is true not only in the case of Parkinson disease, where the evidence for altered mitophagy is particularly strong [70], but also in amyotrophic lateral sclerosis, where mitochondrial function and axonal transport are altered [88], and in Alzheimer disease, where recent evidence points to altered communication be…”
BackgroundChen, H., Detmer, S. A., Ewald, A. J., Griffin, E. E., Fraser, S. E., & Chan, D. C. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200211046 · Cited by 2,601 · cited 1×
“Genetic experiments show that inhibiting fusion shifts the equilibrium towards fission [58], and vice versa [59].”
BackgroundMitochondria: Dynamic Organelles in Disease, Aging, and Development
Chan, D. C. (2006) · Cell · doi:10.1016/j.cell.2006.06.010 · Cited by 1,987
Transcriptional paradigms in mammalian mitochondrial biogenesis and function
Scarpulla, R. C. (2008) · Physiological Reviews · doi:10.1152/physrev.00025.2007 · Cited by 1,666 · cited 1×
“The transcriptional co-activators PGC (peroxisome proliferatoractivated receptor γ coactivator)-1α, PGC-1β, and PRC (PGC-related coactivator) have been identified as activators of a signaling cascade controlling the expression of nuclear-encoded mitochondrial OxPhos components [23].”
BackgroundPINK1-dependent recruitment of Parkin to mitochondria in mitophagy
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L. A., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911187107 · Cited by 1,616
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“For example, there is growing evidence that the accumulation of somatic mutations in mtDNA play a role in the normal aging process [85], in Parkinson disease [86], and perhaps even in cancer [87].”
BackgroundCassidy-Stone, A., Chipuk, J. E., Ingerman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M. J., Shaw, J. T., Hinshaw, J. E., Green, D. R., et al. (2008) · Developmental Cell · doi:10.1016/j.devcel.2007.11.019 · Cited by 1,200
Mitochondrial transcription factor A regulates mtDNA copy number in mammals
Ekstrand, M. I. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh109 · Cited by 919 · cited 1×
“This pathway also regulates mtDNA through modulation of TFAM (transcription factor A, mitochondrial), the mtDNA packaging and transcription factor [24].”
BackgroundGene targeting using zinc finger nucleases
Porteus, M. H., & Carroll, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1125 · Cited by 641 · cited 1×
“In particular, appending a restriction endonuclease to a ZF creates a zinc-finger nuclease (ZFN) that behaves identically to a restriction endonuclease but with a DNA binding specificity that can be tailored to cleave almost any nuclear DNA sequence [76].”
BackgroundMethylene Blue Delays Cellular Senescence and Enhances Key Mitochondrial Biochemical Pathways
Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., & Ames, B. N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9610com · Cited by 272
Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase
Minczuk, M., Papworth, M. A., Kolasinska, P., Murphy, M. P., & Klug, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609502103 · Cited by 166 · cited 1×
“recently targeted both a ZF-DNA methylase [77] and a ZFN [78] to mitochondria.”
BackgroundSteffann, J., Frydman, N., Gigarel, N., Burlet, P., Ray, P. F., Fanchin, R., Feyereisen, E., Kerbrat, V, Tachdjian, G., Bonnefont, J.-P., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.032326 · Cited by 145 · cited 1×
“correction of ptosis, or droopy eyelids [16]; cochlear implants for hearing loss [17]; heart transplantation for cardiopathies [18]); and genetic counseling [19].”
BackgroundPohjoismäki, J. L. O., Goffart, S., Tyynismaa, H., Willcox, S., Ide, T., Kang, D., Suomalainen, A., Karhunen, P. J., Griffith, J. D., Holt, I. J., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016600 · Cited by 122 · cited 1×
“In all of these cases, the heteroplasmic shifting may be most effective in tissues that are especially active in recombination, such as the heart [80,81].”
BackgroundA functionally dominant mitochondrial DNA mutation
Sacconi, S., Salviati, L., Nishigaki, Y., Walker, W. F., Hernandez-Rosa, E., Trevisson, E., Delplace, S., Desnuelle, C., Shanske, S., Hirano, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn073 · Cited by 113 · cited 1×
“Fortunately, however, with but one exception [8], all pathogenic heteroplasmic mtDNA mutations are functionally recessive, in the sense that it takes a large proportion of mutated genomes above a “threshold” for dysfunction (typically >70–80%) to cause disease; conversely, a small increase in the proportion of normal…”
Background
Cited by
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Consequences of oxidative stress in age-related macular degeneration
Jarrett, S. G., & Boulton, M. E. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.03.009 · Cited by 538
Rogers, G. W., Brand, M. D., Petrosyan, S., Ashok, D., Elorza, A. A., Ferrick, D. A., & Murphy, A. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021746 · Cited by 478
Figueira, T. R., Barros, M. H., Camargo, A. A., Castilho, R. F., Ferreira, J. C. B., Kowaltowski, A. J., Sluse, F. E., Souza-Pinto, N. C., & Vercesi, A. E. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4729 · Cited by 419
Epigenetics and cardiovascular disease
Ordovás, J. M., & Smith, C. E. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.104 · Cited by 402
Metadata
- Authors
- Schon, E. A., DiMauro, S., Hirano, M., & Gilkerson, R. W.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 16
- Issue
- 6
- Pages
- 268-276
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2094421676
- Cited by
- 117
- References
- 15
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.